EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

Summary

Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.1 million men were diagnosed with prostate cancer in 2012. Diagnosed incident cases of prostate cancer is defined as malignant neoplasms with the prostate gland as the primary site (ICD-10 code C61, ICD-O-3 code C61.9). The forecast relies on data from national cancer registries, peer-reviewed journal articles, and primary market research. CRPC was defined as an increase in PSA levels after hormone therapy. Stage at diagnosis is classified according to the American Joint Committee on Cancer (AJCC) groupings, which are based on Tumor/Node/Metastasis (TNM) staging, Gleason score, and PSA level (AJCC, 2009).

In 2016, there were 470,099 diagnosed incident cases of prostate cancer in the 7MM. The US had the most cases with 153,623, or 32.68% of cases in the 7MM, followed by Japan (104,389, 22.21% of cases). The number of cases in the 7MM is expected to grow to 548,394 in 2026, for an Annual Growth Rate (AGR) of 1.67%. In 2016, there were 4,452,307 prevalent cases of prostate cancer diagnosed in the previous 10 years in the 7MM. The US made up the largest share of prevalent cases with 1,872,922, or 42.07% of cases in the 7MM. Japan had the next highest number of cases with 698,512, followed by Germany with 542,521. The number of 10-year prevalent cases in the 7MM is expected to increase to 4,634,443 by 2026, for an AGR of 0.41% per year.

Scope

- The Prostate Cancer EpiCast Report provides an overview of the risk factors and global trends for prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. Additionally, this report forecasts 10-year prevalent cases of prostate cancer segmented by castration resistance, metastases, and HRD mutations.
- The Prostate Cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Prostate Cancer EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
- Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
- Understand magnitude of prostate cancer population by risk of biochemical recurrence, castration resistance, metastasis, and HRD mutations.

2
1.List of Tables 3
1.2 List of Figures 3
2 Prostate Cancer: Executive Summary 4
2.Related Reports 7
2.2 Upcoming Reports 7
3 Epidemiology 8
3.Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 9
3.4 Forecast Methodology 11
3.4.Sources 13
3.4.2 Forecast Assumptions and Methods 18
3.5 Epidemiological Forecast for Prostate Cancer (2016-2026) 25
3.5.Diagnosed Incident Cases of Prostate Cancer 25
3.5.2 Age-Specific Incident Cases of Prostate Cancer 26
3.5.3 Incident Cases by Stage at Diagnosis 27
3.5.4 Incident Cases by Risk of Biochemical Recurrence 27
3.5.5 10-Year Diagnosed Prevalent Cases of Prostate Cancer 28
3.5.6 10-Year Prevalent CRPC Cases 30
3.5.7 10-Year Prevalent Metastatic Prostate Cancer Cases 30
3.5.8 10-Year Prevalent mCRPC Cases with HRD Mutations 32
3.6 Discussion 32
3.6.Epidemiological Forecast Insight 32
3.6.2 Limitations of Analysis 33
3.6.3 Strengths of Analysis 34
4 Appendix 35
4.Bibliography 35
4.2 Primary Research - Prescriber Survey 40
4.3 About the Authors 41
4.3.Epidemiologist 41
4.3.2 Reviewers 41
4.3.3 Global Director of Therapy Analysis and Epidemiology 42
4.3.4 Global Head and EVP of Healthcare Operations and Strategy 42
4.4 About GlobalData 43
4.5 Contact Us 43
4.6 Disclaimer 43

List Of Tables

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Prostate Cancer 9
Table 2: AJCC Staging of Prostate Cancer 12
Table 3: Risk Category Definitions 18
Table 4: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages 35 Years, Select Years, 2016-2026 25
Table 5: 7MM, 10-Year Diagnosed Prevalent Cases of Prostate Cancer, Men, Ages 35 Years, Select Years, 2016-2026 29
Table 6: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 40

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available